Tumor cell (TC) contamination of stem cell products can contribute to relapse after high dose chemotherapy and stem cell rescue. A new purging technology using replication-deficient recombinant adenovirus (Adv) containing the p53 tumor suppressor gene (Adv-p53) has been suggested to reduce tumor contamination of autologous stem cell product. We demonstrate herein a safe and effective Adv-p53 purging procedure using four human breast cancer TC lines. Multiple parameters need to be achieved to successfully purge stem cell products, including a high cell:virus ratio, a small incubation volume, a long incubation time and 37°C rather than room temperature. These parameters are all interrelated and equally important for the inhibition of TC clonogenic growth. In our studies, we also observed that Adv could nonspecifically inhibit TC clonogenic growth, although Adv-p53 treatment led to a significantly greater inhibition of clonogenic growth by cells expressing mutated p53. The presence of peripheral stem cell (PSC) products was found to decrease the effect of Adv-p53 on TC clonogenic growth, suggesting that PSC products could compete with TC for infection by recombinant Adv. However, X-Gal staining after incubation with Adv containing-galactosidase demonstrated that PSC products were 2,000-fold more resistant to Adv infection than TC. We conclude that a 4-hour incubation of stem cell products (2 × 108/ml) with 4 × 1011 Adv-p53 particles is sufficient to completely purge TC with no effect on hematopoietic cell function.

Keywords:
Adenovirus, Breast cancer, Clonogenic growth, p53, Purging
1.
Myers SE, Mick R, Williams SF: High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: A role for peripheral blood progenitor transplant. Bone Marrow Transplant 1994;13:449–454.
2.
Ghalie R, Williams SF, Valentino LA, Feingold J, Korenblit AD, Adler SS, Manson S, Pruett J, Cobleigh MA, Wolter J, et al: Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1995;1:40–46.
3.
Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995;13:2483–2489.
4.
Kennedy MJ: High-dose chemotherapy of breast cancer: Is the question answered. J Clin Oncol 1995;13:2477–2479.
5.
To LB, Haylock DN, Simmons PJ, Juttner CA: The biology and clinical uses of blood stem cells. Blood 1997;89:2233–2258.
6.
Vahdat L, Antman KH, Armitage JO, Antman KH: High Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Baltimore, Williams & Wilkins, 1995, p 802.
7.
Brenner M, Rill D, Moen R: Gene marking and autologous bone marrow transplantation. Ann NY Acad Sci 1993;716:204–215.
8.
Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al: Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068–3076.
9.
Sharp JG: Micrometastases and transplantation. J Hematother 1996;5:519–524.
10.
Berger U, Bettelheim R, Mansi JL, Easton D, Coombes RC, Neville AM: The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 1988;90:1–6.
11.
Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G: Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534–1539.
12.
Porro G, Menard S, Tagliabue E, Orefice S, Salvadori B, Squicciarine P, Andreola S, Rilke F, Colnaghi M: Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients. Cancer 1988;61:2407–2411.
13.
Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749–1756.
14.
Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, et al: Detection and viability of tumor cells in peripheral blood stem cell collections breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605–2610.
15.
Chen P, Chen Y, Bookstein R, Lee W: Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990;250:1576–1580.
16.
Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: A critical analysis. Adv Cancer Res 1995;66:71–141.
17.
Wroblewski JM, Lay LT, Van Zant G, Phillips G, Seth P, Curiel D, Meeker TC: Selective elimination (purging) of contaminating malignant cells from hematopoietic stem cell autografts using recombinant adenovirus. Cancer Gene Ther 1996;3/4:257–264.
18.
Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, Gregory RJ, Shepard M, Maneval DC: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 1996;3/2:121–130.
19.
Seth P, Brinkmann U, Schwartz GN, Katayose D, Gress R, Pastan I, Cowan K: Adenovirus-mediated gene transfer to human breast tumor cells: An approach for cancer gene therapy and bone marrow purging. Cancer Res 1996;56:1346–1351.
20.
Chen L, Pulsipher M, Chen D, Sieff C, Elias A, Fine HA, Kufe DW: Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest 1996;98:2539–2548.
21.
Watanabe T, Kuszynski C, Ino K, Heimann DG, Shephard M, Yasui Y, Maneval DC, Talmadge JE: Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors. Blood 1996;87:5032–5039.
22.
Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson S, Wen SF, et al: Development and characterization of recombinant adenovirus encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994;5:1079–1088.
23.
Sharp JG, Kessinger A, Vaughan WP, Mann S, Crouse DA, Dicke K, Masih A, Weisenberger DD: Detection and clinical significance of minimal tumor contamination of peripheral blood stem cell harvests. Int J Cell Cloning 1992;10(suppl 1):92–94.
24.
Ross AA, Cooper BW, Lazarus HM, Peters WP, Vredenburgh JJ, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, et al: Incidence of tumor cell contamination in peripheral blood stem cell collections from breast cancer patients. Proc Am Soc Clin Oncol 1993;12:69a.
25.
Sharp JG, Joshi SS, Armitage JO, Bierman P, Coccia PF, Harrington DS, Kessinger A, Crouse DA, Mann SL, Weisenburger DD: Significance of detection of occult non-Hodgkin’s lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 1992;79:1074–1080.
26.
Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380–383.
27.
Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85–86.
28.
Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for b-cell lymphoma. N Engl J Med 1991;325:1525–1533.
29.
Brockstein BE, Ross AA, Moss TJ, Kahn DG, Hollingsworth K, Williams SF: Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy. J Hematother 1996;5:617–624.
30.
Rummel SA, Van Zant G: Future paradigm for autologous bone marrow transplantation: Tumor purging and ex vivo production of normal stem and progenitor cells. J Hematother 1994;3:213–218.
31.
Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287–2291.
32.
Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P: Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1995;1:889–897.
33.
Seth P, Rosenfeld M, Higginbotham J, Crystal RG: Mechanism of enhancement of DNA expression consequent to cointernalization of a replication-deficient adenovirus and unmodified plasmid DNA. J Virol 1994;68:933–940.
34.
Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval DC, Catino JJ: Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 1997;4/2:129–138.
35.
Li H, Lochmuller H, Wee Yong V, Karpati G, Nalbantoglu J: Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J Neuropathol Exp Neurol 1997;56:872–878.
36.
Seth P, Katayose D, Li Z, Kim M, Wersto R, Craig C, Shanmugan N, Ohri E, Mudahar B, Rakkar AN, et al: A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: A gene therapy approach for drug-resistant cancers. Cancer Gene Ther 1997;4:383–390.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.